<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327791</url>
  </required_header>
  <id_info>
    <org_study_id>1579493</org_study_id>
    <nct_id>NCT04327791</nct_id>
  </id_info>
  <brief_title>COmbination Therapy With Baloxavir and Oseltamavir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)</brief_title>
  <acronym>COMBO 1</acronym>
  <official_title>COmbination Therapy With Baloxavir and Oseltamavir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bassett Healthcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bassett Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled Phase 2-like, investigator-directed
      trial of hospitalized patients with laboratory confirmed influenza. Eligible and consented
      patients will be randomly assigned, in a 1:1 ratio, to one of two groups: Group 1, the
      combination treatment group (oseltamivir and baloxavir); Group 2, the standard treatment
      group (oseltamivir and placebo).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 282 hospitalized patients with laboratory confirmed influenza who provide informed
      consent and meet trial inclusion/exclusion criteria.

      Experimental Design and Methods In a randomized, double-blind, placebo-controlled Phase
      2-like, investigator-directed trial, hospitalized patients with laboratory confirmed
      influenza meeting inclusion and exclusion criteria, will be provided information on the
      trial, offered enrollment, and enrolled randomly in a 1:1 ratio to one of two groups upon
      signing of the study's informed consent form: Group 1, the combination treatment group
      (oseltamivir and baloxavir); Group 2, the standard treatment group (oseltamivir and placebo).

        -  Group 1, the combination treatment group will receive oseltamivir and baloxavir

             -  Oseltamavir: 75 mg po bid for 5 days

             -  Baloxavir: 40 mg po once for wt &lt; 80 kg OR 80 mg po once for wt &gt;/= 80 kg

        -  Group 2, the standard treatment group will receive oseltamivir and placebo

             -  Oseltamavir: 75 mg po bid for 5 days

             -  Placebo: Once

      Oseltamavir dosing may be reduced for patients with decreased renal function as follows, per
      treating physician:

        -  CrCl &gt; 60 mL/minute: No dosage adjustment

        -  CrCl &gt; 30 to 60 mL/minute: 30 mg po bid

        -  CrCl &gt; 10 to 30 mL/minute: 30 mg po qd

        -  HD: 30 mg po once and 30 mg po after each HD session

        -  CAPD: 30 mg po once

        -  CRRT: 30 mg po qd After assignment of a unique study number after signing informed
           consent, baseline data will be collected at time 0 including personal and clinical
           information and protocol directed laboratory specimens - nasopharyngeal swabs for
           influenza PCR for patients who only had a rapid antigen test and blood specimens for
           patients who consent to additional blood drawing (for improved efficacy and safety
           analyses; not required for enrollment). Patients will be given oseltamivir by their
           healthcare providers. Research personnel's only involvement for oseltamivir dosing will
           be to remind providers that earlier treatment improves efficacy. Patients will then be
           given a single dose of baloxavir or placebo by the study's CRC as per a computerized
           random allocation scheme with dose determined by weight (as above); the CRC will notify
           the patient's provider that the patient has been given the single (blinded) dose. At
           time 1, 2, 3, 7, and 30 days, nasopharyngeal swabs will again be obtained, clinical
           information will be obtained from the patient via interview and review of the EMR, and
           blood specimens for patients who consented to additional blood drawing. Follow up will
           continue for 30 days.

      Efficacy and adjudicated safety data points will be assessed by a blinded Data Monitoring
      Committee (DMC) after completion of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inpatient length of stay (LOS)</measure>
    <time_frame>30 days</time_frame>
    <description># of days as inpatient in hospital</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">282</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>baloxavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baloxavir: 40 mg po once for wt &lt; 80 kg OR 80 mg po once for wt &gt;/= 80 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo po once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baloxavir</intervention_name>
    <description>administered PO once</description>
    <arm_group_label>baloxavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>administered PO once</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Adults &gt;/= 18 years old

          2. Laboratory confirmed influenza A and/or B

          3. Hospitalization

          4. Able to and provide written informed consent

          5. Able to commit to 30 days of follow up

          6. Weight &gt; 40 kg

        Exclusion Criteria

          1. ESRD not undergoing hemodialysis (HD) or peritoneal dialysis( CAPD)

          2. Severe hepatic insufficiency,cirrhosis, acute or chronic liver failure

          3. Nausea/vomiting, aspiration risk, or other conditions precluding the ability to use
             oral medications (if patient is NPO including meds)

          4. Influenza medication use within the prior week, other than the initial oseltamavir
             given during this hospitalization for this episode of influenza

          5. Oseltamivir or baloxavir allergy or intolerance

          6. Pregnancy (need negative pregnancy test (urine or blood) in reproductive age women)

          7. Absence of dependable contraception in reproductive age women

          8. Inability to obtain informed consent

          9. Refusal of oseltamavir therapy by patient as baseline treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Freilich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bassett Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jennifer Victory, RN</last_name>
    <phone>6075476965</phone>
    <email>jennifer.victory@bassett.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Freilich, MD</last_name>
    <phone>6075474586</phone>
    <email>daniel.freilich@bassett.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bassett Medical Center</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jennifer Victory, RN</last_name>
      <phone>607-547-6965</phone>
      <email>jennifer.victory@bassett.org</email>
    </contact>
    <investigator>
      <last_name>daniel freilich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bassett Healthcare</investigator_affiliation>
    <investigator_full_name>Daniel Freilich, MD</investigator_full_name>
    <investigator_title>attending physician - hospitalist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Baloxavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

